This Article Full Text Free Full Text (PDF) Free Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to My Personal Article Archive Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (6) Citing Articles via Google Scholar Google Scholar Articles by Metersky, M. L. Articles by Bratzler, D. W. Search for Related Content PubMed PubMed Citation Articles by Metersky, M. L. Articles by Bratzler, D. W.

Antibiotics for Bacteremic Pneumonia^*

Improved Outcomes With Macrolides but Not Fluoroquinolones

^* From the Division of Pulmonary and Critical Care Medicine (Dr. Metersky), University of Connecticut School of Medicine, Farmington, CT; Oklahoma Foundation for Medical Quality, Inc (Drs. Ma and Bratzler), Oklahoma City, OK; and the Department of Epidemiology (Dr. Houck), University of Washington School of Public Health and Community Medicine, Seattle, WA.

Correspondence to: Mark L. Metersky, MD, FCCP, Division of Pulmonary and Critical Care Medicine, University of Connecticut Health Center, 263 Farmington Ave, Farmington, CT 06030-1321; e-mail: Metersky{at}nso.uchc.edu

Abstract

Background: The questions of whether the use of antibiotics that are active against atypical organisms is beneficial in the treatment of community-acquired pneumonia and of the potential mechanisms of any beneficial effects remain unresolved. Proposed mechanisms include activity against atypical organisms vs the immunomodulatory effects of these antibiotics. The study of outcomes of a large cohort of patients with bacteremic pneumonia provides a unique opportunity to address these questions by excluding patients with primary atypical infection.

Methods: We reviewed data from the charts of 2,209 Medicare patients who were admitted to hospitals across the United States from either home or a nursing facility with bacteremic pneumonia between 1998 and 2001. Patients were stratified according to the type of antibiotic treatment. Multivariate modeling was performed to assess the relationship between the class of antibiotic used and several outcome variables.

Results: The initial use of any antibiotic active against atypical organisms was independently associated with a decreased risk of 30-day mortality (odds ratio [OR], 0.76; 95% confidence interval [CI], 0.59 to 0.98; p = 0.03) and hospital admission within 30 days of discharge (OR, 0.67; 95% CI, 0.51 to 0.89; p = 0.02). Further analysis revealed that the benefits of atypical treatment were associated with the use of macrolides, but not the use of fluoroquinolones or tetracyclines, with macrolides conferring lower risks of in-hospital mortality (OR, 0.59; 95% CI, 0.40 to 0.88; p = 0.01), 30-day mortality (OR, 0.61; 95% CI, 0.43 to 0.87; p = 0.007), and hospital readmission within 30 days of discharge (OR, 0.59; 95% CI, 0.42 to 0.85; p = 0.004).

Conclusions: Initial antibiotic treatment including a macrolide agent is associated with improved outcomes in Medicare patients hospitalized with bacteremic pneumonia. These results have implications regarding the mechanism by which the use of a macrolide for treatment of pneumonia is associated with improved outcomes.

Key Words: antibiotics • atypical bacterial forms • bacteremia • outcomes assessment

This article has been cited by other articles:

				K. Z. Vardakas, M. E. Falagas, and M. L. Metersky Interpretation of the Findings of a Cohort Study of Bacteremic Patients With Community-Acquired Pneumonia Chest, November 1, 2007; 132(5): 1715 - 1716. [Full Text] [PDF]

				G. Dimopoulos and M. L. Metersky Antibiotics Selection for Bacteremic Pneumonia Chest, July 1, 2007; 132(1): 360 - 361. [Full Text] [PDF]